XML 30 R10.htm IDEA: XBRL DOCUMENT v3.21.1
4. INTANGIBLE ASSETS
12 Months Ended
Dec. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]  
INTANGIBLE ASSETS

The carrying values of the Company’s finite-lived intangible assets were as follows:

 

    December 31, 2020     December 31, 2019  
          Accumulated                 Accumulated        
    Cost     Amortization     Net     Cost     Amortization     Net  
Product Licenses   $ 3,350,000     $ (264,909 )   $ 3,085,091     $ 1,500,000     $ (48,876 )   $ 1,451,124  
Patent     510,310       (510,310 )     -       510,310       (510,310 )     -  
Software and Other     64,464       (51,889 )     12,575       64,464       (44,394 )     20,070  
                                                 
Total   $ 3,924,774     $ (827,108 )   $ 3,097,666     $ 2,074,774     $ (603,580 )   $ 1,471,194  

 

During the first quarter of 2020, the Company paid a $500,000 milestone payment to Rochal Industries, LLC (“Rochal”), a related party, upon FDA clearance of BIAKŌS Antimicrobial Wound Gel pursuant to the terms of the BIAKŌS License Agreement. The milestone payment was recorded as an addition to intangible assets. During the second quarter of 2020, the Company entered into the Debrider License Agreement which required an initial payment of $1,350,000 to Rochal which consisted of $600,000 in cash and $750,000 in the Company’s common stock.

 

As of December 31, 2020, the weighted-average amortization period for all intangible assets was 12.8 years. Amortization expense related to intangible assets was $223,528 for the twelve months ended December 31, 2020 and $90,011 for the twelve months ended December 31, 2019. The estimated remaining amortization expense as of December 31, 2020 is as follows:

 

 

2021   $ 258,059  
2022     255,645  
2023     250,564  
2024     250,564  
2025     250,564  
Thereafter     1,832,270  
Total   $ 3,097,666  

 

The Company has reviewed the carrying value of intangible assets due to the events and circumstances surrounding the COVID-19 pandemic. The Company does not believe the impact of COVID-19 has created an impairment loss on the Company’s intangible assets as of December 31, 2020. Accordingly, there was no impairment loss recognized on the Company’s intangible assets during the twelve months ended December 31, 2020.